MultiCell Technologies (MCET)

• http://www.multicelltech.com/About-Us/PartnersHome
• About Us
• Discovery Platform & Disease Targets
• Therapeutic Pipeline
• Xenogenics Corp.
• Investor Information
• Contact, Careers & Legal
• Sitema

Company Information:

MultiCell Research & Development Headquarters
68 Cumberland Street, Suite 301
Woonsocket, RI 02895
401.762.0045 Office
info@multicelltech.com

MultiCell Technologies, Inc. Corporate Headquarters
68 Cumberland Street, Suite 301
Woonsocket, RI 02895
401.762.0045 Office
401.762.0098 Fax
info@multicelltech.com

CIK:  0000811779

Multicell Technologies:  Driving the next generation of medical therapies in the life-saving medicine of immune system modulation.

MultiCell is a leading-edge biopharmaceutical company committed to the development and commercialization of breakthrough therapeutics based on a portfolio of new drug candidates and patented drug development technology platforms. 

MultiCell leverages patented methods of modulating the human immune system to treat serious autoimmune diseases, including multiple sclerosis and type-1 diabetes, as well as influenza and other health threats.  Currently, the market for therapies addressing such conditions is estimated at $8 billion worldwide.

The Company's novel technologies include expertise in Toll-like receptors and T-cell targeting to modulate both the innate and adaptive immune systems, enabling the creation of advanced drug candidates that stimulate or suppress the immune system via disease-specific targeting of the immune system. 
 

Management: 

http://www.multicelltech.com/management_team.html 
(note: Chang is no longer CEO, W. Gerald Newmin is. Chang is the head of partially-owned subsidiary Multicell Immunotherapeutics of San Diego and a Director of the Company.)

Board of Directors:

http://www.multicelltech.com/directors.html

Scientific Advisory Board:

http://www.multicelltech.com/advisors.html

Disease Targets & Product Pipeline

MultiCell has focused its technologies on four disease targets: multiple sclerosis (MS); type-1 diabetes; and infectious disease. The Company's therapeutic pipeline includes MCT-125, directed at treating chronic fatigue in MS patients; MCT-175, targeting relapse-remitting MS; MCT-275, for the treatment of type-1 diabetes; and MCT-465, addressing influenza A infection. MultiCell also specializes in developing primary cell immortalization technologies to produce cell-based assay systems for use in drug discovery and for the production of therapeutic proteins.

Discovery Tools Products

http://www.multicelltech.com/discovery_products.html

Recent News: 

http://www.multicelltech.com/newsroom.html

Filings:

http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0000811779&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Transfer Agent:

U.S. Stock Transfer Corp.
Suite 200
Glendale, CA 91204-2991

MORE INFORMATION

MultiCell Technologies, Inc. (MCET) is committed to creating therapeutics, adult stem cells, immunotherapeutics, therapeutic proteins and novel liver-cell based technologies and products for the development of new medicines and treatments for a variety of diseases.

MultiCell Technologies, Inc. is a biopharmaceutical company developing breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development programs focused on modulation of the immune system.

The Company's lead drug candidates target fatigue resulting from multiple sclerosis, relapse-remitting multiple sclerosis, and type-1 diabetes.

Other therapeutic candidates in the MultiCell development pipeline include new antiviral treatments to address influenza and other infectious diseases.

With its majority owned subsidiary, MultiCell Immunotherapeutics (MCTI), MultiCell intends to commercialize new therapeutics for the treatment of various diseases and disorders.

As well as a developer of therapeutics, MultiCell Technologies is an adult stem cell company and a supplier of immortalized cell lines for drug discovery applications.

MultiCell holds key patents relating to novel strategies for the isolation of adult human liver cells, and cell clusters or doublets as well as additional patents in the areas of stem cell technology, and immortalized human hepatocytes.

MultiCell's stem cells are derived from adult tissue, avoiding the ethical and contamination issues associated with embryonic stem cells.

The Company specializes in innovative cell immortalization technologies that lead to the creation of highly functional, continually reproducible, human liver cell lines.

MultiCell is the first company to produce salable liver cell lines that retain functionality, continuously regenerate, and are non-tumorigenic. MCET provides these non-tumorigenic functional hepatic (liver) cells and cell lines to pharmaceutical companies for induction studies and toxicity screening for drug discovery. Hepatocytes metabolize or detoxify drugs or substances ingested into the body. Previously, the pharmaceutical industry had to rely on the occasional harvesting of liver cells from cadavers or cells from a non-human species. Use of MCET's hepatocytes has the potential to save years and millions per new drug. MCET's cells have been independently validated by Hoffmann-LaRoche and Pfizer, as well as XenoTech, LLC.

MultiCell's cellular product expertise also enables future potential for production of biologics for use in diagnostic and therapeutic applications, as well as production of liver-derived therapeutic proteins


MultiCell's majority-owned subsidiary, Xenogenics Corp., owns all rights to the patented Sybiol® synthetic bio-liver therapeutic liver assist device, designed to optimally utilize MultiCell's proprietary, immortalized human hepatocytes. Large animal testing awaits funding or an appropriate partnering opportunity.
 

Formation of MCET: EXTI ( Exten ) Acquisition.

Exten Ventures, the predecessor of Exten Industries, Inc., a Delaware Corporation ("the Company" or "Exten"), was originally incorporated on April 28, 1970. From 1985 to 1990, the Company provided merchant banking services. In September of 1991 the Company acquired all of the outstanding stock of Xenogenex, Inc., a California corporation, ("Xenogenex"). At that time Xenogenex was funding research on xenogeneic transplants and the development of an artificial liver or synthetic bio-liver with a major West Coast medical center. Xenogenex had the rights to the commercial development of the research work being performed by that medical center. In July 1996 all right, title and interest in the artificial liver technology was transferred to the Company. In 1997 the Company formed a new subsidiary, Xenogenics Corporation, a Nevada corporation, (Xenogenics) for the express purpose of holding and developing the Sybiol(R) technology. Xenogenics holds all rights to the extracorporeal artificial liver technology. The company is currently conducting pre-clinical research at Loyola University Medical Center in Chicago, Illinois.
http://orlando.bizjournals.com/gen/company.html?gcode=C4802DFDAA85465785F71F3C4C1BF703§ion=press_releases

Share Structure:
coming

MultiCell Investor Relations
MultiCell Corporate Headquarters
401.762.0045
MCETinvestor@Multicelltech.com

Last update 4.26.2010

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

Rules of the board according to IHUB:
http://www.investorshub.com/boards/complex_terms.asp